Oklahoma Legislature Approves Ibogaine Clinical Trials Bill, Sending Measure to Governor
Oklahoma legislators have approved a bill to fund state-sponsored ibogaine clinical trials, positioning the state as a leader in psychedelic research pending the governor’s signature
Key Points
- 1Oklahoma Senate passed House Bill 3834 to fund ibogaine clinical trials
- 2The bill authorizes state health officials to partner with drug developers for monitored research
- 3Drug developers must match state funding and prioritize Oklahoma residents for future treatments
- 4The legislation establishes safeguards for patient safety and state economic interests
- 5Similar efforts are underway in other states, with varying degrees of legislative success
Oklahoma lawmakers have taken a significant step toward psychedelic reform by passing the Oklahoma Breakthrough Therapy Act, which authorizes state-funded clinical trials of ibogaine. The bill, known officially as House Bill 3834, cleared the State Senate on April 29 after previously passing the House in March. If signed by Governor Kevin Stitt, the legislation will mark a major policy shift in how Oklahoma addresses mental health and substance use disorders, with a focus on research-driven solutions
The measure empowers the State Department of Health to partner with drug developers for tightly regulated clinical trials of ibogaine-based therapeutics. Ibogaine, a naturally occurring psychedelic, has shown promise in treating opioid addiction, post-traumatic stress disorder, and traumatic brain injuries. Under the bill, drug developers must match state investments dollar-for-dollar and present comprehensive plans for FDA approval, participant recruitment, and patient safety
Advocates for the bill have underscored the urgent need for new treatment options, citing the limitations of traditional therapies. Nate Morgans, CEO of the Casey Skudin 343 Fund and a leading advocate, stated, “Our team has worked tirelessly since December to educate, inform, and persuade Oklahoma legislators on the importance of authorizing and funding FDA clinical trials of Ibogaine. This initiative was led by a grassroots effort, employed no lobbyists, and focused on education through truly lived experiences. Our success today serves as a testament to what can be accomplished with determined hearts.”
The legislation also includes rigorous safeguards to protect both patients and the state’s interests. Clinical trials will require extensive pre-treatment medical evaluations and continuous monitoring to minimize risks such as cardiac complications, which have been documented with ibogaine use. Additionally, the bill mandates that Oklahoma residents receive priority access to any future FDA-approved therapies and ensures that the state retains an economic stake in any intellectual property generated by the research
Oklahoma’s move comes as other states, such as Mississippi and Texas, pursue similar research initiatives, though not all efforts have succeeded. For example, a comparable bill in West Virginia was recently vetoed over fiscal concerns. Despite such setbacks, optimism remains high among advocates. Chase Rowan, a US Army Ranger veteran and director at Americans for Ibogaine, emphasized, “This bill is more than a policy change—it offers real hope to so many people who desperately need it.”
From the OG Lab newsroom perspective, Oklahoma’s legislative action could signal a turning point for psychedelic research in the U.S., particularly in the context of mental health and addiction crises. If Governor Stitt signs the bill, it may accelerate multi-state collaboration, stimulate breakthrough medical research, and potentially pave the way for broader regulatory reforms. The outcome is likely to be closely watched by other states considering similar measures
